A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) (NCT06024746)
Combined Efficacy and Safety of an Early, Intensive, Management Strategy With Finerenone and SGLT2 Inhibitor in Patients Hospitalized With Heart Failure (CONFIRMATION-HF)
🩺 Plain-English Summary (8th-Grade Level)
Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.
Who can join: Review the eligibility criteria below.
Location: CON-10004 Fairhope, AL Investigational Site — Fairhope, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (104 Sites)
Showing the first 25 of 104 sites.
- CON-10004 Fairhope, AL Investigational Site — Fairhope, Alabama
- CON-10075 El Centro, CA Investigational Site — El Centro, California
- CON-10024 Sacramento, CA Investigational Site — Sacramento, California
- CON-10023, San Francisco, CA — San Francisco, California
- CON-10109, Van Nuys, CA — Van Nuys, California
- CON-10001, Aurora, CO — Aurora, Colorado
- CON-10005, Denver, CO — Denver, Colorado
- CON-10078, Hialeah, FL — Hialeah, Florida
- CON-10105, Miami, FL — Miami, Florida
- CON-10113, Miramar, FL — Miramar, Florida
- CON-10022 Atlanta, GA Investigational Site — Atlanta, Georgia
- CON-10021, Glenview, IL — Glenview, Illinois
- CON-10041, Island Lake, IL — Island Lake, Illinois
- CON-10025, Naperville, IL — Naperville, Illinois
- CON-10019, Peoria, IL — Peoria, Illinois
- CON-10064, Merrillville, IN — Merrillville, Indiana
- CON-10080, Lexington, KY — Lexington, Kentucky
- CON-10086, Louisville, Kentucky — Louisville, Kentucky
- CON-10079, Paducah, KY — Paducah, Kentucky
- CON-10030 Baton Rouge, LA Investigational Site — Baton Rouge, Louisiana
- CON-10090, West Monroe, LA — West Monroe, Louisiana
- CON-10002 Kansas City, MO Investigative Site — Kansas City, Missouri
- CON-10018, Omaha, NE — Omaha, Nebraska
- CON-10318, Charlotte, NC — Charlotte, North Carolina
- CON-10119, Centerville, OH — Centerville, Ohio
📞 Contact the Study Coordinator
Phone: (303) 860-9900
Email: info@cpcmed.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Heart Failure
- REDUCE LAP-HFREF TRIAL — New York, New York
- Physiological Effects Ketone Ester in Heart — Cleveland, Ohio
- DASH Diet in Heart Failure Outpatients — Sacramento, California
- Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients — Huntsville, Alabama
- LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System. — Birmingham, Alabama
- A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation — Alexander City, Alabama
Explore by condition: All Heart Failure clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.